Opdivo-chemo combo improves survival in gastric, esophageal cancer

BMS’ anticancer drug Opdivo (nivolumab) in combination with chemotherapy as a first-line treatment of gastric and esophageal cancer improved the overall survival (OS) and progression-free survival (PFS) in gastric and esophageal cancer patients, compared to chemotherapy alone in a phase-3 trial, BSM said.

http://www.koreabiomed.com/news/articleView.html?idxno=9290

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *